Veeral Desai - Mar 23, 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Strategy & Dev. Officer
Signature
/s/ Steve Meetre, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Mar 23, 2023
Transactions value $
-$3,084,290
Form type
4
Date filed
3/27/2023, 04:06 PM
Previous filing
Mar 17, 2023
Next filing
Apr 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $68.1K +22.7K +8.21% $3.00* 299K Mar 23, 2023 Direct F1
transaction AGL Common Stock Sale -$652K -22.7K -7.58% $28.71 277K Mar 23, 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $292K +97.3K +35.16% $3.00* 374K Mar 24, 2023 Direct F1
transaction AGL Common Stock Sale -$2.79M -97.3K -26.01% $28.70 277K Mar 24, 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -22.7K -1.38% $0.00 1.62M Mar 23, 2023 Common Stock 22.7K $3.00 Direct F5
transaction AGL Options (Rights to Buy) Options Exercise $0 -97.3K -6.02% $0.00 1.52M Mar 24, 2023 Common Stock 97.3K $3.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.50 to $28.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.50 to $28.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on April 27, 2017 and vested on September 14, 2021.